Breast cancers are ER-positive, HER2-positive, or triple negative. The type of breast cancer you have determines the type of medication you take. Learn more from experts at WebMD.
然而,近年来,有一批HER2表达水平低(HER2-low)的乳腺癌患者引起了研究者的关注。这部分患者的HER2水平介于HER2阴性和HER2过表达之间,他们的治疗和预后一直不明确。2023年4月,Breast Cancer Research and Treatment杂志发表了一篇题为HER-2 ...
HER2-positive breast cancer has a distinctive biology, wherein amplification of the HER2 oncogene leads to a cascade of downstream effects. While in the past this distinctive biology was associated with a higher risk of recurrence and impaired long-term outcome, our current understanding of this ...
Fifteen patients with HER2 equivocal invasive breast cancer had Oncotype DX performed. Of these, 13 underwent alternative probe HER2 FISH yielding 4 negative, 6 equivocal and 3 positive results. All 15 cases were classified as HER2 negative by Oncotype DX rt-PCR, including the three cases which ...
在接受新辅助化疗的早期乳腺癌患者中,HER2低表达与HER2零表达患者化疗敏感性或预 后无明显差异。提示目前乳腺癌NAC时,无需单独考虑HER2低表达或HER2零表达状态。 参考文献 Ilie SM, Briot N, Constantin G, Roussot N, Ilie A, Ber...
Hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) breast cancer is the most prevalent type of breast cancer, in which endocrine therapy resistance and distant relapse remain unmet challenges. Accurate molecular classification is urgently required for guiding pre...
HER2-positivebreastcancer46her2阳性乳腺癌 系统标签: breastpositive乳腺癌trastuzumab阳性pertuzumab Series.thelancetPublishedonlineDecember6,2016http://dx.doi/10.1016/S0140-6736(16)32417-51Breastcancer2HER2-positivebreastcancerSibylleLoibl,LucaGianniAnti-HER2treatmentforHER2-positivebreastcancerhaschangedthenatural...
数量的 proteomics 透露在 CD146 促使中的时代介入在乳腺癌细胞中的上皮-mesenchymal 的过渡。 [translate] aClinical Significance of HER2-Positive and Triple-Negative Status in Small (≤ 1 cm) Node-Negative Breast Cancer. HER2正面和三倍消极状态的临床意义在小 (≤ 1 cm) 结消极乳腺癌。 [translate] ...
Biologics: Targets & Therapy Dovepress open access to scientific and medical research Open Access Full Text Article HER2 breast cancer therapies: a review review Conleth G Murphy Shanu Modi Breast Cancer Medicine Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY,...
[5] Seock-Ah Im, et al. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. N Engl J Med. 2019; 381(4): 307-316. [6] Harbeck N, et al. Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer tre...